Hypothesis-Generating Brief: ABT-263

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile the outcome-class source counts (n) and directional coding between the abstract, the Findings Map header table, and each outcome-class subsection. Provide a single authoritative table with per-class n, claim count, direction tally, directness tally, and limitations, and ensure all prose is consistent with it.
2. Clarify the scope statement: explicitly state which included sources are direct ABT-263 (navitoclax) studies versus other senolytics used as adjacent context, and justify why each non-ABT-263 source is included in an ABT-263 evidence map.
3. Correct the evidence_type field in the source bundle for any record marked 'review' that is actually a primary study (e.g., Gonzales 2023, Tripathi 2025, Mahoney 2025, Jean 2024), and update the directness coding in the Findings Map accordingly.
4. Expand the Tensions and Gaps section: currently it contains a single sentence that does not surface specific disagreements. List representative cross-source conflicts (e.g., ABT-263 efficacy in Delval 2026 vs Wakita 2026; Kawamoto 2026 null replication vs prior positive senolytic claims; Gonzales 2023 CSF IL-6 increase vs expected anti-inflammatory effect) and connect each to a concrete next-step study design.
5. For the single-source outcome classes (longevity, deficiency prevalence, parts of cardiometabolic and skeletal), explicitly state in the Limitations or Findings Map that the direction signal is single-source and must be treated as hypothesis-generating, with no within-corpus replication.
6. For the bundle entries without DOIs (R24, R28, R29, R31, R32), either supply DOIs/PMIDs, downgrade them from high-confidence to verification-limited, or remove them and adjust the admitted source count and claim totals accordingly.

Major issues

• The Findings Map section is internally inconsistent: the header table and abstract state Immune and Inflammation has n=7 sources with 138 claims, but the prose subsection reports only 2 included sources with directional coding null=2, and the abstract counts 7/33 in that class. The count of sources and directionality should be reconciled across abstract, table, and prose.
• The abstract and Findings Map are partly inaccurate regarding outcome class sizes. For example, Longevity is reported as n=1 with positive signal (Ichim 2026) but the abstract groups longevity among classes with positive signals, and Ichim 2026 is a senolytic–regenerative combination (SenoVax + pMSCs), not a direct ABT-263 (navitoclax) efficacy test, so its attribution to the ABT-263 corpus should be clarified.
• Several in-text source citations (e.g., Ichim 2026, Mahoney 2026, Delval 2026, Kawamoto 2026, Wakita 2026, Falahatgaroshibi 2026, Novais 2026, Tripathi 2025b, Justice 2019, Nambiar 2023, Farr 2024, Gonzales 2023, Shimizu 2025, Su 2026) match bundle entries, but the evidence_type for several bundle rows is miscoded as 'review' when the listed studies are primary research (e.g., Gonzales 2023, Tripathi 2025, Mahoney 2025, Jean 2024), undermining the source_grounding assessment and the directness coding reported in the Findings Map.
• The Immune and Inflammation outcome class is described as having 7 sources in the table and abstract, yet the prose subsection explicitly states only 2 sources are included and treats the rest as assigned to adjacent classes. This makes the boundary of the evidence map non-auditable and must be reconciled.

Minor issues

• The title frames ABT-263 (navitoclax) but the corpus includes substantial D+Q, fisetin, and non-ABT-263 senolytic evidence (e.g., Ichim 2026 uses SenoVax, Furuuchi 2026 uses Rhodiola rosea). The scope statement should clarify the inclusion rationale for non-ABT-263 sources and how they map to the ABT-263 question.
• Several bundle entries (R24, R28, R29, R31, R32) have null DOIs and are listed as 'corpus' source_type with no PubMed/journal record; their standing as 'high-confidence' sources should be clarified.
• The 'Deficiency Prevalence' outcome class is unusual in the senolytic/ABT-263 context and rests on a single source (Su 2026, which is a cyclophosphamide-induced POI model). Its label as 'deficiency prevalence' is misleading; relabeling or explicit justification is warranted.
• Year metadata: multiple sources are listed as 2026 in the bundle and text, which is inconsistent with the stated knowledge cutoff; if these are preprints or in-press, that status should be noted.
• The exact p-values and CIs attributed to Farr 2024 in the Limitations section are not directly visible in the bundle excerpt beyond CTx P=0.611 and P1NP P=0.020/0.024; the additional P=0.035 and P=0.004 values should be traced to specific endpoints in the source.

Reviewer note

This evidence map of ABT-263 (navitoclax) and adjacent senolytic literature is broadly appropriate in format: it reports a tiered evidence profile across 33 admitted sources, surfaces null, positive, and mixed signals per outcome class, and avoids collapsing the corpus into a single efficacy claim. The Limitations section is unusually strong, explicitly flagging the absence of phase 3 RCTs, the mechanism-to-clinic gap, narrow enrolled populations, surrogate-endpoint concerns, and the senolytic-resistant senescent-cell ceiling. However, several material inconsistencies prevent an accept. The Findings Map is internally contradictory: the header table assigns 7 sources and 138 claims to Immune and Inflammation, while the prose subsection states only 2 included sources and treats the rest as adjacent. The abstract's claim of 'positive signals in immune and inflammation' is not clearly supported by the per-class direction tally. The longevity outcome class rests on Ichim 2026, which is a SenoVax + pMSC combination, not a direct ABT-263 efficacy test, so its placement in an ABT-263 evidence map requires explicit justification. The source bundle miscodes several primary studies as 'review', which propagates into the directness coding of the Findings Map. The Tensions and Gaps section is a single sentence and does not live up to the evidence-map requirement to surface specific disagreements. Finally, the scope statement does not clearly distinguish direct ABT-263 evidence from adjacent senolytic context, given that D+Q, fisetin, fisetin/Rhodiola, and DEL-1 sources dominate the corpus. These are bounded but non-trivial fixes: reconciling counts, correcting evidence_type, clarifying scope, and expanding Tensions and Gaps. No claims require retraction or scope reset. The manuscript is salvageable as an evidence map but requires the revisions above before it is internally consistent and auditable.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis